Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ATOVAQUONE AND RIFABUTINE-LOADED NANOCAPSULES - FORMULATION STUDIES
Autore:
DALENCON F; AMJAUD Y; LAFFORGUE C; DEROUIN F; FESSI H;
Indirizzi:
UNIV LYON 1,ISPB,LAB RECH & DEV PHARM GALEN IND,8 AVE ROCKEFELLER F-69008 LYON FRANCE UNIV LYON 1,ISPB,LAB RECH & DEV PHARM GALEN IND F-69008 LYON FRANCE HOP ST LOUIS,LAB PARASITOL MYCOL F-75475 PARIS 10 FRANCE
Titolo Testata:
International journal of pharmaceutics
fascicolo: 1, volume: 153, anno: 1997,
pagine: 127 - 130
SICI:
0378-5173(1997)153:1<127:AARN-F>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
TOXOPLASMA-GONDII;
Keywords:
TOXOPLASMOSIS; TOXOPLASMA GONDII; RIFABUTINE; ATOVAQUONE; NANOCAPSULES;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
8
Recensione:
Indirizzi per estratti:
Citazione:
F. Dalencon et al., "ATOVAQUONE AND RIFABUTINE-LOADED NANOCAPSULES - FORMULATION STUDIES", International journal of pharmaceutics, 153(1), 1997, pp. 127-130

Abstract

Atovaquone and rifabutine have potential therapeutic activity againsttoxoplasmosis but the low water solubility of these drugs reduces their bioavailability. Their formulation as a colloidal suspension of poly (D,L) lactic acid nanocapsules can increase that effectiveness. The atovaquone formulation was more stable than the rifabutine one and wasinjected at 15 mg/kg per day by the intragastric route to mice infected with Toxoplasma gondii. A better survival rate was observed in micetreated with nanocapsules than in mice treated with a suspension of the drug. Parasites were undetectable in brains of mice treated with atovaquone nanocapsules one month previously whereas control mice treated with drug suspension showed signs of central nervous system infection. (C) 1997 Elsevier Science B.V.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/07/20 alle ore 03:21:49